Mobocertinib launch price in China

Mobocertinib (Mobocertinib) is a new generation of non-small cell lung cancer (NSCLC) treatment drug with a targeted mechanism of action, specifically targeting patients with EGFR (epidermal growth factor receptor) gene mutations.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.

Mobosetinib is mainly suitable for patients with advanced or metastatic NSCLC with positive EGFR gene mutations. Mutations in these genes are relatively common in NSCLC, especially in Asian populations. Mobosetinib is also indicated for patients whose disease has progressed after prior treatment with other EGFR TKIs, particularly those carrying the EGFR T790M mutation.

Mobosetinib is a tyrosine kinase inhibitor (TKI). Its main function is to treat NSCLC by inhibiting the activity of EGFR protein. EGFR is an abnormal protein commonly found in NSCLC patients, which prompts cancer cells to grow and divide rapidly. Mobosetinib is unique in that it also effectively inhibits the EGFR T790M mutation, which often leads to resistance to other EGFR TKI therapies.